Imaging Manifestations of the Leukodystrophies, Inherited Disorders of White Matter

Radiologic Clinics of North America

Volumn 52, Issue 2, 2014, Pages 279-319

  Yang, Edward ^a   Prabhu, Sanjay P ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Demyelination; Dysmyelination; Inborn error of metabolism; Leukodystrophy; Spectroscopy; White matter

Indexed keywords

18Q DELETION SYNDROME; AICARDI GOUTIERES SYNDROME; ALEXANDER DISEASE; CANAVAN DISEASE; CHILDHOOD ADRENOLEUKODYSTROPHY; COCKAYNE SYNDROME; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; FUCOSIDOSIS; GALACTOSEMIA; GLOBOID CELL LEUKODYSTROPHY; GRAY MATTER; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMAGE ANALYSIS; L 2 HYDROXYGLUTARIC ACIDURIA; LEUKODYSTROPHY; LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND INCREASED LACTATE; LOWE SYNDROME; MAPLE SYRUP URINE DISEASE; MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYST; METACHROMATIC LEUKODYSTROPHY; MUCOPOLYSACCHARIDOSIS; MYELINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; REVIEW; SANDHOFF DISEASE; SIALIC ACID STORAGE DISEASE; SUBCORTEX; SUSCEPTIBILITY WEIGHTED IMAGING; TAY SACHS DISEASE; UREA CYCLE DISORDER; WHITE MATTER;

DEMYELINATION; DYSMYELINATION; INBORN ERROR OF METABOLISM; LEUKODYSTROPHY; SPECTROSCOPY; WHITE MATTER;

DIAGNOSIS, DIFFERENTIAL; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; NERVE FIBERS, MYELINATED;

EID: 84894614818     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.11.008     Document Type: Review

References (262)

1. Seitelberger F. Structural manifestations of leukodystrophies. Neuropediatrics 1984, 15(Suppl):53-61.
2. Menkes J.H. The leukodystrophies. NEngl J Med 1990, 322(1):54-55.
3. van der Knaap M., Valk J. Classification of myelin disorders. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
4. Leite C.C., Lucato L.T., Martin M.G., et al. Merosin-deficient congenital muscular dystrophy (CMD): a study of 25 Brazilian patients using MRI. Pediatr Radiol 2005, 35(6):572-579.
5. Mercuri E., Topaloglu H., Brockington M., et al. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol 2006, 63(2):251-257.
6. van der Knaap M.S., Smit L.M., Barth P.G., et al. Magnetic resonance imaging in classification of congenital muscular dystrophies with brain abnormalities. Ann Neurol 1997, 42(1):50-59.
7. Poll-The B.T., Gartner J. Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta 2012, 1822(9):1421-1429.
8. van der Knaap M., Valk J. Magnetic resonance ofmyelination and myelin disorders 2005, Springer-Verlag, Berlin.
9. Patay Z. Metabolic disorders. Pediatric neuroradiology 2005, vol. 1:543-721. Springer-Verlag, Berlin.
10. Barkovich A.J., Patay Z. Metabolic, toxic, and inflammatory brain disorders. Pediatric neuroimaging 2012, 81-239. Lippincott Williams & Wilkins, Philadelphia. A.J. Barkovich (Ed.).
11. Leijser L.M., de Vries L.S., Rutherford M.A., et al. Cranial ultrasound in metabolic disorders presenting in the neonatal period: characteristic features and comparison with MR imaging. AJNR Am J Neuroradiol 2007, 28(7):1223-1231.
12. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol 2005, 15(11):2284-2303.
13. Melhem E.R., Loes D.J., Georgiades C.S., et al. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000, 21(5):839-844.
14. Cecil K.M. MR spectroscopy of metabolic disorders. Neuroimaging Clin N Am 2006, 16(1):87-116. viii.
15. Cakmakci H., Pekcevik Y., Yis U., et al. Diagnostic value of proton MR spectroscopy and diffusion-weighted MR imaging in childhood inherited neurometabolic brain diseases and review of the literature. Eur J Radiol 2010, 74(3):e161-e171.
16. Lange T., Dydak U., Roberts T.P., et al. Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006, 27(4):895-901.
17. Afifi A.K., Menezes A.H., Reed L.A., et al. Atypical presentation of X-linked childhood adrenoleukodystrophy with an unusual magnetic resonance imaging pattern. JChild Neurol 1996, 11(6):497-499.
18. van der Knaap M.S., Salomons G.S., Li R., et al. Unusual variants of Alexander's disease. Ann Neurol 2005, 57(3):327-338.
19. Barkovich A.J. Concepts of myelin and myelination in neuroradiology. AJNR Am J Neuroradiol 2000, 21(6):1099-1109.
20. van der Knaap M.S., Breiter S.N., Naidu S., et al. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology 1999, 213(1):121-133.
21. Bonkowsky J.L., Nelson C., Kingston J.L., et al. The burden of inherited leukodystrophies in children. Neurology 2010, 75(8):718-725.
22. Vanderver A., Hussey H., Schmidt J.L., et al. Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders. Semin Pediatr Neurol 2012, 19(4):219-223.
23. Heim P., Claussen M., Hoffmann B., et al. Leukodystrophy incidence in Germany. Am J Med Genet 1997, 71(4):475-478.
24. Kohlschutter A., Eichler F. Childhood leukodystrophies: a clinical perspective. Expert Rev Neurother 2011, 11(10):1485-1496.
25. Kaye C.I., Committee on Genetics, Accurso F., et al. Introduction to the newborn screening fact sheets. Pediatrics 2006, 118(3):1304-1312.
26. Woodward K.J. The molecular and cellular defects underlying Pelizaeus-Merzbacher disease. Expert Rev Mol Med 2008, 10:e14.
27. van der Knaap M., Valk J. Pelizaeus-Merzbacher disease and X-linked spastic paraplegia type 2. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
28. Southwood C.M., Garbern J., Jiang W., et al. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 2002, 36(4):585-596.
29. Gow A., Lazzarini R.A. Acellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat Genet 1996, 13(4):422-428.
30. Hobson G.M., Garbern J.Y. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol 2012, 32(1):62-67.
31. van der Knaap M.S., Valk J. The reflection of histology in MR imaging of Pelizaeus-Merzbacher disease. AJNR Am J Neuroradiol 1989, 10(1):99-103.
32. Linnankivi T., Tienari P., Somer M., et al. 18q deletions: clinical, molecular, and brain MRI findings of 14 individuals. Am J Med Genet A 2006, 140(4):331-339.
33. Feenstra I., Vissers L.E., Orsel M., et al. Genotype-phenotype mapping of chromosome 18q deletions by high-resolution array CGH: an update of the phenotypic map. Am J Med Genet A 2007, 143A(16):1858-1867.
34. Lancaster J.L., Cody J.D., Andrews T., et al. Myelination in children with partial deletions of chromosome 18q. AJNR Am J Neuroradiol 2005, 26(3):447-454.
35. Linnankivi T.T., Autti T.H., Pihko S.H., et al. 18q-syndrome: brain MRI shows poor differentiation of gray and white matter on T2-weighted images. JMagn Reson Imaging 2003, 18(4):414-419.
36. Tanaka R., Iwasaki N., Hayashi M., et al. Abnormal brain MRI signal in 18q-syndrome not due to dysmyelination. Brain Dev 2012, 34(3):234-237.
37. Verheijen F.W., Verbeek E., Aula N., et al. Anew gene, encoding an anion transporter, is mutated in sialic acid storage diseases. Nat Genet 1999, 23(4):462-465.
38. Adams D, Gahl WA. Free sialic acid storage disorders. GeneReviews 2008. Available at: Accessed April 2, 2013. http://www.ncbi.nlm.nih.gov/books/NBK1470/.
39. Leroy PL. Sialuria. GeneReviews 2012. Available at: Accessed April 2, 2013. http://www.ncbi.nlm.nih.gov/books/NBK1164/.
40. Sonninen P., Autti T., Varho T., et al. Brain involvement in Salla disease. AJNR Am J Neuroradiol 1999, 20(3):433-443.
41. Haataja L., Parkkola R., Sonninen P., et al. Phenotypic variation and magnetic resonance imaging (MRI) in Salla disease, a free sialic acid storage disorder. Neuropediatrics 1994, 25(5):238-244.
42. Varho T., Komu M., Sonninen P., et al. Anew metabolite contributing to N-acetyl signal in 1H MRS of the brain in Salla disease. Neurology 1999, 52(8):1668-1672.
43. Mochel F., Yang B., Barritault J., et al. Free sialic acid storage disease without sialuria. Ann Neurol 2009, 65(6):753-757.
44. van der Knaap M., Valk J. Fucosidosis. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
45. Steenweg M.E., Vanderver A., Blaser S., et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010, 133(10):2971-2982.
46. Prietsch V., Arnold S., Kraegeloh-Mann I., et al. Severe hypomyelination as the leading neuroradiological sign in a patient with fucosidosis. Neuropediatrics 2008, 39(1):51-54.
47. Oner A.Y., Cansu A., Akpek S., et al. Fucosidosis: MRI and MRS findings. Pediatr Radiol 2007, 37(10):1050-1052.
48. Mamourian A.C., Hopkin J.R., Chawla S., et al. Characteristic MR spectroscopy in fucosidosis: invitro investigation. Pediatr Radiol 2010, 40(8):1446-1449.
49. Uhlenberg B., Schuelke M., Ruschendorf F., et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet 2004, 75(2):251-260.
50. Bugiani M., Al Shahwan S., Lamantea E., et al. GJA12 mutations in children with recessive hypomyelinating leukoencephalopathy. Neurology 2006, 67(2):273-279.
51. Magen D., Georgopoulos C., Bross P., et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet 2008, 83(1):30-42.
52. Vaurs-Barriere C., Deville M., Sarret C., et al. Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol 2009, 65(1):114-118.
53. Feinstein M., Markus B., Noyman I., et al. Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation. Am J Hum Genet 2010, 87(6):820-828.
54. Tetreault M., Choquet K., Orcesi S., et al. Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. Am J Hum Genet 2011, 89(5):652-655.
55. Bernard G., Chouery E., Putorti M.L., et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet 2011, 89(3):415-423.
56. Harreld J.H., Smith E.C., Prose N.S., et al. Trichothiodystrophy with dysmyelination and central osteosclerosis. AJNR Am J Neuroradiol 2010, 31(1):129-130.
57. Zara F., Biancheri R., Bruno C., et al. Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract. Nat Genet 2006, 38(10):1111-1113.
58. van der Knaap M.S., Naidu S., Pouwels P.J., et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol 2002, 23(9):1466-1474.
59. Simons C., Wolf N.I., McNeil N., et al. Ade novo mutation in the beta-Tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet 2013, 92(5):767-773.
60. Hamosh A, Scharer G, Van Hove J. Glycine encephalopathy. In: Pagon RA, Bird TD, Dolan CR, etal, editors. GeneReviews. Seattle (WA): 1993. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1357/.
61. Mourmans J., Majoie C.B., Barth P.G., et al. Sequential MR imaging changes in nonketotic hyperglycinemia. AJNR Am J Neuroradiol 2006, 27(1):208-211.
62. Khong P.L., Lam B.C., Chung B.H., et al. Diffusion-weighted MR imaging in neonatal nonketotic hyperglycinemia. AJNR Am J Neuroradiol 2003, 24(6):1181-1183.
63. Viola A., Chabrol B., Nicoli F., et al. Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia. Pediatr Res 2002, 52(2):292-300.
64. Gabis L., Parton P., Roche P., et al. Invivo 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia. JNeuroimaging 2001, 11(2):209-211.
65. Fridovich-Keil J.L. Galactosemia: the good, the bad, and the unknown. JCell Physiol 2006, 209(3):701-705.
66. Ridel K.R., Leslie N.D., Gilbert D.L. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol 2005, 33(3):153-161.
67. van der Knaap M., Valk J. Galactosemia. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
68. Otaduy M.C., Leite C.C., Lacerda M.T., et al. Proton MR spectroscopy and imaging of a galactosemic patient before and after dietary treatment. AJNR Am J Neuroradiol 2006, 27(1):204-207.
69. Wang Z.J., Berry G.T., Dreha S.F., et al. Proton magnetic resonance spectroscopy of brain metabolites in galactosemia. Ann Neurol 2001, 50(2):266-269.
70. Leegwater P.A., Boor P.K., Yuan B.Q., et al. Identification of novel mutations in MLC1 responsible for megalencephalic leukoencephalopathy with subcortical cysts. Hum Genet 2002, 110(3):279-283.
71. van der Knaap M.S., Boor I., Estevez R. Megalencephalic leukoencephalopathy with subcortical cysts: chronic white matter oedema due to a defect in brain ion and water homoeostasis. Lancet Neurol 2012, 11(11):973-985.
72. van der Knaap M.S., Barth P.G., Stroink H., et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol 1995, 37(3):324-334.
73. Lopez-Hernandez T., Ridder M.C., Montolio M., et al. Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism. Am J Hum Genet 2011, 88(4):422-432.
74. Aicardi J., Goutieres F. Aprogressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984, 15(1):49-54.
75. Baraitser M., Brett E.M., Piesowicz A.T. Microcephaly and intracranial calcification in two brothers. JMed Genet 1983, 20(3):210-212.
76. Aicardi J, Crow YJ, Stephenson J. Aicardi-Goutieres syndrome. GeneReviews 2012. Available at: Accessed April 3, 2013. http://www.ncbi.nlm.nih.gov/books/NBK1475/.
77. Crow Y.J., Hayward B.E., Parmar R., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006, 38(8):917-920.
78. Crow Y.J., Leitch A., Hayward B.E., et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 2006, 38(8):910-916.
79. Rice G.I., Bond J., Asipu A., et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009, 41(7):829-832.
80. Rice G.I., Kasher P.R., Forte G.M., et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet 2012, 44(11):1243-1248.
81. Vogt J., Agrawal S., Ibrahim Z., et al. Striking intrafamilial phenotypic variability in Aicardi-Goutieres syndrome associated with the recurrent Asian founder mutation in RNASEH2C. Am J Med Genet A 2013, 161A(2):338-342.
82. Rice G., Patrick T., Parmar R., et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007, 81(4):713-725.
83. Chahwan C., Chahwan R. Aicardi-Goutieres syndrome: from patients to genes and beyond. Clin Genet 2012, 81(5):413-420.
84. Ravenscroft J.C., Suri M., Rice G.I., et al. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet A 2011, 155A(1):235-237.
85. Rice G., Newman W.G., Dean J., et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007, 80(4):811-815.
86. Uggetti C., La Piana R., Orcesi S., et al. Aicardi-Goutieres syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol 2009, 30(10):1971-1976.
87. Chen X., DeLellis R.A., Hoda S.A. Adrenoleukodystrophy. Arch Pathol Lab Med 2003, 127(1):119-120.
88. Eichler F.S., Ren J.Q., Cossoy M., et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?. Ann Neurol 2008, 63(6):729-742.
89. van der Knaap M., Valk J. X-linked adrenoleukodystrophy. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
90. Steinberg SJ, Moser AB, Raymond GV. X-linked adrenoleukodystrophy. GeneReviews 2012. Available at: Accessed April 4, 2013. http://www.ncbi.nlm.nih.gov/books/NBK1315/.
91. Ito R., Melhem E.R., Mori S., et al. Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology 2001, 56(4):544-547.
92. Carrozzo R., Bellini C., Lucioli S., et al. Peroxisomal acyl-CoA-oxidase deficiency: two new cases. Am J Med Genet A 2008, 146A(13):1676-1681.
93. van der Knaap M.S., Wassmer E., Wolf N.I., et al. MRI as diagnostic tool in early-onset peroxisomal disorders. Neurology 2012, 78(17):1304-1308.
94. Kumar A.J., Kohler W., Kruse B., et al. MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol 1995, 16(6):1227-1237.
95. Dubey P., Fatemi A., Huang H., et al. Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. Ann Neurol 2005, 58(5):758-766.
96. Loes D.J., Fatemi A., Melhem E.R., et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003, 61(3):369-374.
97. Dekaban A.S., Constantopoulos G. Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain. Acta Neuropathol 1977, 39(1):1-7.
98. van der Knaap M., Valk J. Mucopolysaccharidoses. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
99. Azevedo A.C., Artigalas O., Vedolin L., et al. Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI. JInherit Metab Dis 2013, 36(2):357-362.
100. Barone R., Nigro F., Triulzi F., et al. Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). Neuropediatrics 1999, 30(5):270-274.
101. Manara R., Priante E., Grimaldi M., et al. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. JInherit Metab Dis 2011, 34(3):763-780.
102. Matheus M.G., Castillo M., Smith J.K., et al. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 2004, 46(8):666-672.
103. Vedolin L., Schwartz I.V., Komlos M., et al. Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. AJNR Am J Neuroradiol 2007, 28(6):1029-1033.
104. Wang R.Y., Cambray-Forker E.J., Ohanian K., et al. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab 2009, 98(4):406-411.
105. Fan Z., Styner M., Muenzer J., et al. Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. AJNR Am J Neuroradiol 2010, 31(7):1319-1323.
106. Attree O., Olivos I.M., Okabe I., et al. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 1992, 358(6383):239-242.
107. McPherson P.S., Garcia E.P., Slepnev V.I., et al. Apresynaptic inositol-5-phosphatase. Nature 1996, 379(6563):353-357.
108. Lewis RA, Nussbaum RL, Brewer ED. Lowe syndrome. In: Pagon RA, Bird TD, Dolan CR, etal, editors. GeneReviews. Seattle (WA): 1993. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1480/.
109. O'Tuama L.A., Laster D.W. Oculocerebrorenal syndrome: case report with CT and MR correlates. AJNR Am J Neuroradiol 1987, 8(3):555-557.
110. Demmer L.A., Wippold F.J., Dowton S.B. Periventricular white matter cystic lesions in Lowe (oculocerebrorenal) syndrome. A new MR finding. Pediatr Radiol 1992, 22(1):76-77.
111. Carroll W.J., Woodruff W.W., Cadman T.E. MR findings in oculocerebrorenal syndrome. AJNR Am J Neuroradiol 1993, 14(2):449-451.
112. Schneider J.F., Boltshauser E., Neuhaus T.J., et al. MRI and proton spectroscopy in Lowe syndrome. Neuropediatrics 2001, 32(1):45-48.
113. Yuksel A., Karaca E., Albayram M.S. Magnetic resonance imaging, magnetic resonance spectroscopy, and facial dysmorphism in a case of Lowe syndrome with novel OCRL1 gene mutation. JChild Neurol 2009, 24(1):93-96.
114. Bergoffen J., Scherer S.S., Wang S., et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993, 262(5142):2039-2042.
115. Bird TD. Charcot-Marie-Tooth neuropathy X type 1. GeneReviews 2012. 2013. Available at: Accessed April 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20301548.
116. Shy M.E., Siskind C., Swan E.R., et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007, 68(11):849-855.
117. Paulson H.L., Garbern J.Y., Hoban T.F., et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002, 52(4):429-434.
118. Taylor R.A., Simon E.M., Marks H.G., et al. The CNSphenotype of X-linked Charcot-Marie-Tooth disease: more than a peripheral problem. Neurology 2003, 61(11):1475-1478.
119. Hanemann C.O., Bergmann C., Senderek J., et al. Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation. Arch Neurol 2003, 60(4):605-609.
120. Laugel V. Cockayne syndrome: the expanding clinical and mutational spectrum. Mech Ageing Dev 2013, 134(5-6):161-170.
121. Nance M.A., Berry S.A. Cockayne syndrome: review of 140 cases. Am J Med Genet 1992, 42(1):68-84.
122. Koob M., Laugel V., Durand M., et al. Neuroimaging in Cockayne syndrome. AJNR Am J Neuroradiol 2010, 31(9):1623-1630.
123. Adachi M., Kawanami T., Ohshima F., et al. MR findings of cerebral white matter in Cockayne syndrome. Magn Reson Med Sci 2006, 5(1):41-45.
124. van der Knaap M., Valk J. Cockayne syndrome. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
125. van Berge L., Kevenaar J., Polder E., et al. Pathogenic mutations causing LBSL affect mitochondrial aspartyl-tRNA synthetase in diverse ways. Biochem J 2013, 450(2):345-350.
126. Scheper G.C., van der Klok T., van Andel R.J., et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007, 39(4):534-539.
127. van der Knaap M.S., van der Voorn P., Barkhof F., et al. Anew leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol 2003, 53(2):252-258.
128. van der Knaap M., Valk J. Leukoencephalopathy with brain stem and spinal cord involvement and elevated white matter lactate. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
129. Steenweg M.E., van Berge L., van Berkel C.G., et al. Early-onset LBSL: how severe does it get?. Neuropediatrics 2012, 43(6):332-338.
130. Taft R.J., Vanderver A., Leventer R.J., et al. Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity. Am J Hum Genet 2013, 92(5):774-780.
131. Fluharty AL. Arylsulfatase A deficiency. In: Pagon RA, Bird TD, Dolan CR, etal, editors. GeneReviews. Seattle (WA): 1993. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1130/.
132. Al-Hassnan Z.N., Al Dhalaan H., Patay Z., et al. Sphingolipid activator protein B deficiency: report of 9 Saudi patients and review of the literature. JChild Neurol 2009, 24(12):1513-1519.
133. Stevens R.L., Fluharty A.L., Kihara H., et al. Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am J Hum Genet 1981, 33(6):900-906.
134. Kihara H., Tsay K.K., Fluharty A.L. Genetic complementation in somatic cell hybrids of cerebroside sulfatase activator deficiency and metachromatic leukodystrophy fibroblasts. Hum Genet 1984, 66(4):300-301.
135. MacFaul R., Cavanagh N., Lake B.D., et al. Metachromatic leucodystrophy: review of 38 cases. Arch Dis Child 1982, 57(3):168-175.
136. Polten A., Fluharty A.L., Fluharty C.B., et al. Molecular basis of different forms of metachromaticleukodystrophy. NEngl J Med 1991, 324(1):18-22.
137. Groeschel S., Kehrer C., Engel C., et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. JInherit Metab Dis 2011, 34(5):1095-1102.
138. Eichler F., Grodd W., Grant E., et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009, 30(10):1893-1897.
139. Maia A.C., da Rocha A.J., da Silva C.J., et al. Multiple cranial nerve enhancement: a new MR imaging finding in metachromatic leukodystrophy. AJNR Am J Neuroradiol 2007, 28(6):999.
140. Faerber E.N., Melvin J., Smergel E.M. MRI appearances of metachromatic leukodystrophy. Pediatr Radiol 1999, 29(9):669-672.
141. Caro P.A., Marks H.G. Magnetic resonance imaging and computed tomography in Pelizaeus-Merzbacher disease. Magn Reson Imaging 1990, 8(6):791-796.
142. Dziewas R., Stogbauer F., Oelerich M., et al. Acase of adrenomyeloneuropathy with unusual lesion pattern in magnetic resonance imaging. JNeurol 2001, 248(4):341-342.
143. Nishio H., Kodama S., Matsuo T., et al. Cockayne syndrome: magnetic resonance images of the brain in a severe form with early onset. JInherit Metab Dis 1988, 11(1):88-102.
144. van der Voorn J.P., Pouwels P.J., Kamphorst W., et al. Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol 2005, 26(3):442-446.
145. Onur M.R., Senol U., Mihci E., et al. Tigroid pattern on magnetic resonance imaging in Lowe syndrome. JClin Neurosci 2009, 16(1):112-114.
146. Cleary M.A., Walter J.H., Wraith J.E., et al. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994, 344(8915):87-90.
147. Leuzzi V., Tosetti M., Montanaro D., et al. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. JInherit Metab Dis 2007, 30(2):209-216.
148. Willemsen M.A., Van Der Graaf M., Van Der Knaap M.S., et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004, 25(4):649-657.
149. van der Knaap M., Valk J. Hyperhomocysteinemias. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
150. Wilcken B. Leukoencephalopathies associated with disorders of cobalamin and folate metabolism. Semin Neurol 2012, 32(1):68-74.
151. Mano T., Ono J., Kaminaga T., et al. Proton MR spectroscopy of Sjogren-Larsson's syndrome. AJNR Am J Neuroradiol 1999, 20(9):1671-1673.
152. Striano P., Specchio N., Biancheri R., et al. Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy Behav 2007, 10(1):187-191.
153. van der Knaap M., Valk J. Neuronal ceroid lipofuscinoses. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
154. van der Knaap M.S., Pronk J.C., Scheper G.C. Vanishing white matter disease. Lancet Neurol 2006, 5(5):413-423.
155. Leegwater P.A., Vermeulen G., Konst A.A., et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 2001, 29(4):383-388.
156. van der Lei H.D., Steenweg M.E., Barkhof F., et al. Characteristics of early MRI in children and adolescents with vanishing white matter. Neuropediatrics 2012, 43(1):22-26.
157. Kaul R., Gao G.P., Aloya M., et al. Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994, 55(1):34-41.
158. Kaul R., Gao G.P., Balamurugan K., et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 1993, 5(2):118-123.
159. Matalon R., Michals K., Sebesta D., et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988, 29(2):463-471.
160. Baslow M.H. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. JMol Neurosci 2003, 21(3):185-190.
161. Matalon R.M., Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Front Biosci 2000, 5:D307-D311.
162. Namboodiri A.M., Moffett J.R., Arun P., et al. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol 2006, 576:145-163. [discussion 361-3].
163. van der Knaap M., Valk J. Canavan disease. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
164. Brismar J., Brismar G., Gascon G., et al. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990, 11(4):805-810.
165. McAdams H.P., Geyer C.A., Done S.L., et al. CT and MR imaging of Canavan disease. AJNR Am J Neuroradiol 1990, 11(2):397-399.
166. Toft P.B., Geiss-Holtorff R., Rolland M.O., et al. Magnetic resonance imaging in juvenile Canavan disease. Eur J Pediatr 1993, 152(9):750-753.
167. Yalcinkaya C., Benbir G., Salomons G.S., et al. Atypical MRI findings in Canavan disease: a patient with a mild course. Neuropediatrics 2005, 36(5):336-339.
168. Zafeiriou D.I., Kleijer W.J., Maroupoulos G., et al. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings. Brain Dev 1999, 21(3):205-208.
169. Grodd W., Krageloh-Mann I., Klose U., et al. Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy. Radiology 1991, 181(1):173-181.
170. Janson C.G., McPhee S.W., Francis J., et al. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics 2006, 37(4):209-221.
171. Rzem R., Veiga-da-Cunha M., Noel G., et al. Agene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A 2004, 101(48):16849-16854.
172. Kranendijk M., Struys E.A., Salomons G.S., et al. Progress in understanding 2-hydroxyglutaric acidurias. JInherit Metab Dis 2012, 35(4):571-587.
173. Steenweg M.E., Salomons G.S., Yapici Z., et al. L-2-Hydroxyglutaric aciduria: pattern of MR imaging abnormalities in 56 patients. Radiology 2009, 251(3):856-865.
174. Topcu M., Erdem G., Saatci I., et al. Clinical and magnetic resonance imaging features of L-2-hydroxyglutaric acidemia: report of three cases in comparison with Canavan disease. JChild Neurol 1996, 11(5):373-377.
175. Patay Z., Mills J.C., Lobel U., et al. Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. AJNR Am J Neuroradiol 2012, 33(5):940-943.
176. Ye D., Ma S., Xiong Y., et al. R-2-Hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 2013, 23(3):274-276.
177. Losman J.A., Looper R.E., Koivunen P., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339(6127):1621-1625.
178. van der Knaap M.S., Jakobs C., Hoffmann G.F., et al. D-2-hydroxyglutaric aciduria: further clinical delineation. JInherit Metab Dis 1999, 22(4):404-413.
179. Choi C., Ganji S.K., DeBerardinis R.J., et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012, 18(4):624-629.
180. Pope W.B., Prins R.M., Albert Thomas M., et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. JNeurooncol 2012, 107(1):197-205.
181. Brenner M., Johnson A.B., Boespflug-Tanguy O., et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001, 27(1):117-120.
182. Li R., Johnson A.B., Salomons G., et al. Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 2005, 57(3):310-326.
183. Messing A., Li R., Naidu S., et al. Archetypal and new families with Alexander disease and novel mutations in GFAP. Arch Neurol 2012, 69(2):208-214.
184. Hagemann T.L., Connor J.X., Messing A. Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. JNeurosci 2006, 26(43):11162-11173.
185. Hsiao V.C., Tian R., Long H., et al. Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAP. JCell Sci 2005, 118(Pt 9):2057-2065.
186. Messing A., Brenner M., Feany M.B., et al. Alexander disease. JNeurosci 2012, 32(15):5017-5023.
187. Gorospe JR. Alexander disease. In: Pagon RA, Bird TD, Dolan CR, etal, editors. GeneReviews. Seattle (WA): 1993. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1172/.
188. van der Knaap M., Valk J. GM1 gangliosidosis and GM2 gangliosidosis. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
189. van der Knaap M.S., Naidu S., Breiter S.N., et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001, 22(3):541-552.
190. van der Knaap M.S., Ramesh V., Schiffmann R., et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006, 66(4):494-498.
191. Pareyson D., Fancellu R., Mariotti C., et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 2008, 131(Pt 9):2321-2331.
192. Stumpf E., Masson H., Duquette A., et al. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 2003, 60(9):1307-1312.
193. Jeyakumar M., Butters T.D., Dwek R.A., et al. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 2002, 28(5):343-357.
194. Okada S., O'Brien J.S. Generalized gangliosidosis: beta-galactosidase deficiency. Science 1968, 160(3831):1002-1004.
195. Nishimoto J., Nanba E., Inui K., et al. GM1-gangliosidosis (genetic beta-galactosidase deficiency): identification of four mutations in different clinical phenotypes among Japanese patients. Am J Hum Genet 1991, 49(3):566-574.
196. Yoshida K., Oshima A., Shimmoto M., et al. Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases. Am J Hum Genet 1991, 49(2):435-442.
197. Okada S., O'Brien J.S. Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component. Science 1969, 165(3894):698-700.
198. Lalley P.A., Rattazzi M.C., Shows T.B. Human beta-D-N-acetylhexosaminidases A and B: expression and linkage relationships in somatic cell hybrids. Proc Natl Acad Sci U S A 1974, 71(4):1569-1573.
199. Myerowitz R., Costigan F.C. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. JBiol Chem 1988, 263(35):18587-18589.
200. O'Dowd B.F., Klavins M.H., Willard H.F., et al. Molecular heterogeneity in the infantile and juvenile forms of Sandhoff disease (O-variant GM2 gangliosidosis). JBiol Chem 1986, 261(27):12680-12685.
201. Gilbert F., Kucherlapati R., Creagan R.P., et al. Tay-Sachs' and Sandhoff's diseases: the assignment of genes for hexosaminidase A and B to individual human chromosomes. Proc Natl Acad Sci U S A 1975, 72(1):263-267.
202. Sandhoff K., Conzelmann E., Nehrkorn H. Substrate specificity of hexosaminidase A isolated from the liver of a patient with a rare form (AB variant) of infantile GM2 gangliosidosis and control tissues. Adv Exp Med Biol 1978, 101:727-730.
203. Chen B., Rigat B., Curry C., et al. Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2. Am J Hum Genet 1999, 65(1):77-87.
204. Brunetti-Pierri N., Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008, 94(4):391-396.
205. Kaback MM, Desnick RJ. Hexosaminidase A deficiency. GeneReviews 1993. 2013. Available at: Accessed April 21, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20301397.
206. Bley A.E., Giannikopoulos O.A., Hayden D., et al. Natural history of infantile G(M2) gangliosidosis. Pediatrics 2011, 128(5):e1233-e1241.
207. Maegawa G.H., Stockley T., Tropak M., et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 2006, 118(5):e1550-e1562.
208. Frey L.C., Ringel S.P., Filley C.M. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol 2005, 62(6):989-994.
209. Erol I., Alehan F., Pourbagher M.A., et al. Neuroimaging findings in infantile GM1 gangliosidosis. Eur J Paediatr Neurol 2006, 10(5-6):245-248.
210. Chen C.Y., Zimmerman R.A., Lee C.C., et al. Neuroimaging findings in late infantile GM1 gangliosidosis. AJNR Am J Neuroradiol 1998, 19(9):1628-1630.
211. Imamura A., Miyajima H., Ito R., et al. Serial MR imaging and 1H-MR spectroscopy in monozygotic twins with Tay-Sachs disease. Neuropediatrics 2008, 39(5):259-263.
212. Inglese M., Nusbaum A.O., Pastores G.M., et al. MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis. AJNR Am J Neuroradiol 2005, 26(8):2037-2042.
213. Streifler J.Y., Gornish M., Hadar H., et al. Brain imaging in late-onset GM2 gangliosidosis. Neurology 1993, 43(10):2055-2058.
214. Uyama E., Terasaki T., Watanabe S., et al. Type 3 GM1 gangliosidosis: characteristic MRI findings correlated with dystonia. Acta Neurol Scand 1992, 86(6):609-615.
215. Roze E., Paschke E., Lopez N., et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005, 20(10):1366-1369.
216. De Grandis E., Di Rocco M., Pessagno A., et al. MR imaging findings in 2 cases of late infantile GM1 gangliosidosis. AJNR Am J Neuroradiol 2009, 30(7):1325-1327.
217. van der Knaap M., Valk J. Globoid cell leukodystrophy: Krabbe disease. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
218. Suzuki K., Suzuki Y. Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc Natl Acad Sci U S A 1970, 66(2):302-309.
219. Spiegel R., Bach G., Sury V., et al. Amutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. Mol Genet Metab 2005, 84(2):160-166.
220. Svennerholm L., Vanier M.T., Mansson J.E. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. JLipid Res 1980, 21(1):53-64.
221. Wenger DA. Krabbe disease. GeneReviews. 2013. Available at: Accessed April 25, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20301416.
222. Choi S., Enzmann D.R. Infantile Krabbe disease: complementary CT and MR findings. AJNR Am J Neuroradiol 1993, 14(5):1164-1166.
223. Livingston J.H., Graziano C., Pysden K., et al. Intracranial calcification in early infantile Krabbe disease: nothing new under the sun. Dev Med Child Neurol 2012, 54(4):376-379.
224. Finelli D.A., Tarr R.W., Sawyer R.N., et al. Deceptively normal MR in early infantile Krabbe disease. AJNR Am J Neuroradiol 1994, 15(1):167-171.
225. Escolar M.L., Poe M.D., Smith J.K., et al. Diffusion tensor imaging detects abnormalities in the corticospinal tracts of neonates with infantile Krabbe disease. AJNR Am J Neuroradiol 2009, 30(5):1017-1021.
226. Guo A.C., Petrella J.R., Kurtzberg J., et al. Evaluation of white matter anisotropy in Krabbe disease with diffusion tensor MR imaging: initial experience. Radiology 2001, 218(3):809-815.
227. Loes D.J., Peters C., Krivit W. Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method. AJNR Am J Neuroradiol 1999, 20(2):316-323.
228. Sasaki M., Sakuragawa N., Takashima S., et al. MRI and CT findings in Krabbe disease. Pediatr Neurol 1991, 7(4):283-288.
229. Bernal O.G., Lenn N. Multiple cranial nerve enhancement in early infantile Krabbe's disease. Neurology 2000, 54(12):2348-2349.
230. Jones B.V., Barron T.F., Towfighi J. Optic nerve enlargement in Krabbe's disease. AJNR Am J Neuroradiol 1999, 20(7):1228-1231.
231. Morana G., Biancheri R., Dirocco M., et al. Enhancing cranial nerves and cauda equina: an emerging magnetic resonance imaging pattern in metachromatic leukodystrophy and krabbe disease. Neuropediatrics 2009, 40(6):291-294.
232. Nagar V.A., Ursekar M.A., Krishnan P., et al. Krabbe disease: unusual MRI findings. Pediatr Radiol 2006, 36(1):61-64.
233. Vasconcellos E., Smith M. MRI nerve root enhancement in Krabbe disease. Pediatr Neurol 1998, 19(2):151-152.
234. Zafeiriou D.I., Michelakaki E.M., Anastasiou A.L., et al. Serial MRI and neurophysiological studies in late-infantile Krabbe disease. Pediatr Neurol 1996, 15(3):240-244.
235. Farina L., Bizzi A., Finocchiaro G., et al. MR imaging and proton MR spectroscopy in adult Krabbe disease. AJNR Am J Neuroradiol 2000, 21(8):1478-1482.
236. Zhang B., Zhao Y., Harris R.A., et al. Molecular defects in the E1 alpha subunit of the branched-chain alpha-ketoacid dehydrogenase complex that cause maple syrup urine disease. Mol Biol Med 1991, 8(1):39-47.
237. Nobukuni Y., Mitsubuchi H., Akaboshi I., et al. Maple syrup urine disease. Complete defect of the E1 beta subunit of the branched chain alpha-ketoacid dehydrogenase complex due to a deletion of an 11-bp repeat sequence which encodes a mitochondrial targeting leader peptide in a family with the disease. JClin Invest 1991, 87(5):1862-1866.
238. Fisher C.W., Lau K.S., Fisher C.R., et al. A17-bp insertion and a Phe215-Cys missense mutation in thedihydrolipoyl transacylase (E2) mRNA from a thiamine-responsive maple syrup urine disease patient WG-34. Biochem Biophys Res Commun 1991, 174(2):804-809.
239. Herring W.J., Litwer S., Weber J.L., et al. Molecular genetic basis of maple syrup urine disease in a family with two defective alleles for branched chain acyltransferase and localization of the gene to human chromosome 1. Am J Hum Genet 1991, 48(2):342-350.
240. Strauss KA, Puffenberger EG, Morton DH. Maple syrup urine disease. GeneReviews. 2013. Available at: Accessed April 26, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20301495.
241. Shaag A., Saada A., Berger I., et al. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet 1999, 82(2):177-182.
242. Liu T.C., Kim H., Arizmendi C., et al. Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. Proc Natl Acad Sci U S A 1993, 90(11):5186-5190.
243. van der Knaap M., Valk J. Maple syrup urine disease. Magnetic resonance of myelination and myelin disorders 2005, Springer-Verlag, Berlin.
244. Brismar J., Aqeel A., Brismar G., et al. Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. AJNR Am J Neuroradiol 1990, 11(6):1219-1228.
245. Bhat M., Prasad C., Bindu P.S., et al. Unusual imaging findings in brain and spinal cord in two siblings with maple syrup urine disease. JNeuroimaging 2013, 23(4):540-542.
246. Bindu P.S., Shehanaz K.E., Christopher R., et al. Intermediate maple syrup urine disease: neuroimaging observations in 3 patients from South India. JChild Neurol 2007, 22(7):911-913.
247. Sener R.N. Diffusion magnetic resonance imaging in intermediate form of maple syrup urine disease. JNeuroimaging 2002, 12(4):368-370.
248. Cavalleri F., Berardi A., Burlina A.B., et al. Diffusion-weighted MRI of maple syrup urine disease encephalopathy. Neuroradiology 2002, 44(6):499-502.
249. Felber S.R., Sperl W., Chemelli A., et al. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993, 33(4):396-401.
250. Jan W., Zimmerman R.A., Wang Z.J., et al. MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. Neuroradiology 2003, 45(6):393-399.
251. Lanpher BC, Gropman A, Chapman KA, etal. Urea Cycle Disorders Consortium. Urea cycle disorders overview. GeneReviews. 2013. Available at: Accessed April 30, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20301396.
252. Takanashi J., Barkovich A.J., Cheng S.F., et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. AJNR Am J Neuroradiol 2003, 24(6):1184-1187.
253. Majoie C.B., Mourmans J.M., Akkerman E.M., et al. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. AJNR Am J Neuroradiol 2004, 25(1):32-35.
254. McKinney A.M., Lohman B.D., Sarikaya B., et al. Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. AJNR Am J Neuroradiol 2010, 31(8):1471-1479.
255. Poveda M.J., Bernabeu A., Concepcion L., et al. Brain edema dynamics in patients with overt hepatic encephalopathy A magnetic resonance imaging study. Neuroimage 2010, 52(2):481-487.
256. Choi C.G., Yoo H.W. Localized proton MR spectroscopy in infants with urea cycle defect. AJNR Am J Neuroradiol 2001, 22(5):834-837.
257. Finsterer J., Jarius C., Eichberger H. Phenotype variability in 130 adult patients with respiratory chain disorders. JInherit Metab Dis 2001, 24(5):560-576.
258. Koene S., Rodenburg R.J., van der Knaap M.S., et al. Natural disease course and genotype-phenotype correlations in Complex I deficiency caused by nuclear gene defects: what we learned from 130 cases. JInherit Metab Dis 2012, 35(5):737-747.
259. Sofou K., Steneryd K., Wiklund L.M., et al. MRI of the brain in childhood-onset mitochondrial disorders with central nervous system involvement. Mitochondrion 2013, 13(4):364-371.
260. Chu B.C., Terae S., Takahashi C., et al. MRI of the brain in the Kearns-Sayre syndrome: report of four cases and a review. Neuroradiology 1999, 41(10):759-764.
261. Twomey E.L., Naughten E.R., Donoghue V.B., et al. Neuroimaging findings in glutaric aciduria type 1. Pediatr Radiol 2003, 33(12):823-830.
262. Morava E., Smeitink J.A. Mitochondria and mitochondrial disorders. Magnetic resonance of myelination and myelin disorders 2005, 195-203. Springer-Verlag, Berlin. M. van der Knaap, J. Valk (Eds.).